Abcl stock forecast

Find the latest AbCellera Biologics Inc. ABCL analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports. Date Range. investment rating..

AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to earnings of $0.54 per share a year ago.ABCL stock forecast for 2023 – 2027. Last updated: October 5, 2023. ABCL. AbCellera Biologics Inc. 4.43 D 1.14% (0.05) Are you interested in AbCellera Biologics Inc. stocks prediction? If yes, then on this page you will find useful information about the dynamics of the ABCL stock price in 2022-2027. Is ABCL a good long term stock? When should ...Future criteria checks 2/6. AbCellera Biologics's earnings are forecast to decline at 12.1% per annum while its annual revenue is expected to grow at 23.9% per …

Did you know?

Future criteria checks 2/6. AbCellera Biologics's earnings are forecast to decline at 12.1% per annum while its annual revenue is expected to grow at 23.9% per …Find the latest Bionano Genomics, Inc. (BNGO) stock quote, history, news and other vital information to help you with your stock trading and investing.The Bilibili Inc. stock forecast for tomorrow is $ 11.34, which would represent a 0.50% gain compared to the current price. In the next week, the price of BILI is expected to decrease by -8.68% and hit $ 10.31. As far as the long-term Bilibili Inc. stock forecast is concerned, here’s what our predictions are currently suggesting.

May 26, 2023 · ABCL Stock Performance: A Look at May 26, 2023. On May 26, 2023, Abcellera Biologics Inc (ABCL) saw a significant increase in its stock price, with shares trading at $28.00, up 306.39% from the previous day’s closing price. This surge in price can be attributed to the positive outlook of the 9 analysts who offer 12-month price forecasts for ABCL. AbCellera Biologics (ABCL) Risk Factors. Public companies are required to disclose risks that can affect the business and impact the stock. These disclosures are known as “Risk Factors”. Companies disclose these risks in their yearly (Form 10-K), quarterly earnings (Form 10-Q), or “foreign private issuer” reports (Form 20-F).Nov 16, 2023 · Get powerful stock screeners & detailed portfolio analysis. Subscribe Now See Plans & Pricing. AbCellera Biologics stock news, updates & related news. Find out why AbCellera Biologics's (ABCL) news sentiment is 14.35% more negative in relation to stocks in the Healthcare sector. 4 ago 2023 ... As of Friday, August 04, AbCellera Biologics Inc's ABCL share price has dipped by 13.34%, which has investors questioning if this is right ...After dumping hundreds of millimetres of rain across New South Wales and Queensland, severe storms have moved south, where they are forecast to bring up to …

Adbri (ASX:ABC) pays an annual dividend of A$0.12 per share and currently has a dividend yield of 5.74%. ABC has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio is 75.00%. This payout ratio is at a healthy, sustainable level, below 75%.Find the latest Bristol-Myers Squibb Company (BMY) stock quote, history, news and other vital information to help you with your stock trading and investing.Are you tired of spending countless hours manually tracking your inventory? Are you looking for a way to improve your decision making and forecasting processes? Look no further than a free inventory tracking template. ….

Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. Abcl stock forecast. Possible cause: Not clear abcl stock forecast.

Future criteria checks 2/6. AbCellera Biologics's earnings are forecast to decline at 12.1% per annum while its annual revenue is expected to grow at 23.9% per …Dec 1, 2023 · According to 10 stock analysts, the average 12-month stock price forecast for NIO Inc. stock is $12.44, which predicts an increase of 73.99%. The lowest target is $8.00 and the highest is $18. On average, analysts rate NIO Inc. stock as a buy. Planning a trip can be an exciting but challenging task. From booking accommodations to creating an itinerary, there are countless details to consider. One crucial aspect that should never be overlooked is checking the 7-day weather forecas...

We use big data and artificial intelligence to forecast the stock price of AbCellera Biologics Inc Ordinary Shares - ABCL. Our stock price predictions cover a period of 3 months. We cover the US equity market.Nov 29, 2023 · Analyst projections state that ABCL is forecast to be at a low of $10.00 and a high of $34.00. In order for the stock price to hit the forecast high, the stock would need to plunge -618.82% from its current level, while the stock would need to crash -111.42% from its current level to reach the projected low.

is lyft cheaper than uber Nov 21, 2023 · Future criteria checks 4/6. Palantir Technologies is forecast to grow earnings and revenue by 34.8% and 18% per annum respectively. EPS is expected to grow by 33.7% per annum. Return on equity is forecast to be 18.4% in 3 years. vanguard consumer staples fundfanduel big wins Analyst Recommendations on AbCellera Biologics Inc. Piper Sandler Assumes AbCellera Biologics at Overweight With $20 Price Target. Oct. 13. MT. Benchmark Adjusts AbCellera Biologics' Price Target to $12 From $20, Keeps Buy Rating. Aug. 31. MT. Goldman Sachs Adjusts AbCellera Biologics' Price Target to $24 From $27, Keeps Buy Rating.Of 9 analyst(s) looking at the stock, 0 analyst(s) give ABCL a Sell rating. 0 of those analysts rate the stock as Overweight while 1 advise Hold as 8 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. ... Revenue is forecast to shrink -30.00% this quarter before jumping 14.30% for the next one. ge healthcare spinoff Insiders purchased significant amount of AbCellera stock directly after Q1. See why I ABCL shares are increasingly attractive for long-term, patient investors.AbCellera Biologics (ABCL) Risk Factors. Public companies are required to disclose risks that can affect the business and impact the stock. These disclosures are known as “Risk Factors”. Companies disclose these risks in their yearly (Form 10-K), quarterly earnings (Form 10-Q), or “foreign private issuer” reports (Form 20-F). vermont digger newsarizona dental plansge leadership Weather forecasting plays a crucial role in our daily lives, helping us plan our activities and make informed decisions. But have you ever wondered how meteorologists are able to accurately predict the weather? One of the key components in ... mgp Earnings announcement* for ABC: May 02, 2023. AmerisourceBergen Corporation (Holding Co) is expected* to report earnings on 05/02/2023 before market open. The report will be for the fiscal Quarter ...Price Performance Review of ABCL. On Monday, AbCellera Biologics Inc [NASDAQ:ABCL] saw its stock jump 2.91% to $4.60. On the same session, the stock had its day’s lowest price of $4.345, but rose to a high of $4.69. Over the last five days, the stock has gained 15.58%. AbCellera Biologics Inc shares have fallen nearly -54.59% since the year ... mad money lightning roundbest food stockaustralian forex trading brokers A high-level overview of AbCellera Biologics Inc. (ABCL) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Analyst Forecast. According to 41 analysts, the average rating for NVDA stock is "Strong Buy." The 12-month stock price forecast is $609.89, which is an increase of 30.42% from the latest price.